Last Updated on June 22, 2023

Cardiovascular and Hematological Disorders - Drug Targets- Impact Score, Ranking, SJR, h-index, Citescore, Rating, Publisher, ISSN, and Other Important Details


Published By: Bentham Science Publishers B.V.

Abbreviation: Cardiovasc. Hematol. Disord. - Drug Targets




Impact Score

The impact Score or journal impact score (JIS) is equivalent to Impact Factor. The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly mean number of citations of articles published in the last two years in a given journal, as indexed by Clarivate's Web of Science. On the other hand, Impact Score is based on Scopus data.

1.08

SJR

 0.270

h-Index

 44

Rank

 16147

Important Details

Title Cardiovascular and Hematological Disorders - Drug Targets
Standard Abbreviation Cardiovasc. Hematol. Disord. - Drug Targets
Type of Publication Journal
Discipline Cardiology and Cardiovascular Medicine (Q3); Hematology (Q3); Medicine (miscellaneous) (Q3); Pharmacology (Q3); Molecular Medicine (Q4)
Impact Score 1.08
SCImago Journal Rank (SJR) 0.270
h-index 44
Overall Rank 16147
Publisher Name Bentham Science Publishers B.V.
Publication Country United Arab Emirates
International Standard Serial Number (ISSN) 1871529X
Coverage and History 2006-2022
Best Quartile Q3
Total Citations Received
(Last 3 Year)
122

About Cardiovascular and Hematological Disorders - Drug Targets


Cardiovascular and Hematological Disorders - Drug Targets is a journal published by Bentham Science Publishers B.V.. This journal covers the area[s] related to Cardiology and Cardiovascular Medicine, Hematology, Medicine (miscellaneous), Pharmacology, Molecular Medicine, etc. The coverage history of this journal is as follows: 2006-2022. The rank of this journal is 16147. This journal's impact score, h-index, and SJR are 1.08, 44, and 0.270, respectively. The ISSN of this journal is/are as follows: 1871529X.

The best quartile of Cardiovascular and Hematological Disorders - Drug Targets is Q3. This journal has received a total of 122 citations during the last three years (Preceding 2022).


Cardiovascular and Hematological Disorders - Drug Targets Impact Score 2022-2023


The latest impact score (IS) of the Cardiovascular and Hematological Disorders - Drug Targets is 1.08. It is computed in the year 2023 as per its definition and based on Scopus data. 1.08

It is decreased by a factor of around 0.01, and the percentage change is -0.92% compared to the preceding year 2021, indicating a falling trend.

The impact score (IS), also denoted as the Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Prediction of Cardiovascular and Hematological Disorders - Drug Targets Impact Score 2023


Impact Score 2022 of Cardiovascular and Hematological Disorders - Drug Targets is 1.08. If a similar downward trend continues, IS may decrease in 2023 as well.


Impact Score Graph


Check below the Impact Score trends of Cardiovascular and Hematological Disorders - Drug Targets. This is based on Scopus data.


Year Impact Score (IS)
2023/2024 Coming Soon
2022 1.08
2021 1.09
2020 1.57
2019 1.41
2018 1.00
2017 1.13
2016 1.33
2015 1.81
2014 1.78

Cardiovascular and Hematological Disorders - Drug Targets h-index


  Table Setting

The h-index of Cardiovascular and Hematological Disorders - Drug Targets is 44. By definition of the h-index, this journal has at least 44 published articles with more than 44 citations.

What is h-index?

The h-index (also known as the Hirsch index or Hirsh index) is a scientometric parameter used to evaluate the scientific impact of the publications and journals. It is defined as the maximum value of h such that the given Journal has published at least h papers and each has at least h citations.




Cardiovascular and Hematological Disorders - Drug Targets ISSN


The International Standard Serial Number (ISSN) of Cardiovascular and Hematological Disorders - Drug Targets is/are as follows: 1871529X.

The ISSN is a unique 8-digit identifier for a specific publication like Magazine or Journal. The ISSN is used in the postal system and in the publishing world to identify the articles that are published in journals, magazines, newsletters, etc. This is the number assigned to your article by the publisher, and it is the one you will use to reference your article within the library catalogues.

ISSN code (also called as "ISSN structure" or "ISSN syntax") can be expressed as follows: NNNN-NNNC
Here, N is in the set {0,1,2,3...,9}, a digit character, and C is in {0,1,2,3,...,9,X}

Table Setting

Cardiovascular and Hematological Disorders - Drug Targets Ranking and SCImago Journal Rank (SJR)


The Cardiovascular and Hematological Disorders - Drug Targets is ranked 16147 among 27955 Journals, Conferences, and Book Series. As per SJR, this journal is ranked 0.270.

SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.


Cardiovascular and Hematological Disorders - Drug Targets Publisher


Table Setting

The publisher of Cardiovascular and Hematological Disorders - Drug Targets is Bentham Science Publishers B.V.. The publishing house of this journal is located in the United Arab Emirates. Its coverage history is as follows: 2006-2022.


Call For Papers (CFPs)


Please check the official website of this journal to find out the complete details and Call For Papers (CFPs).


Abbreviation


The International Organization for Standardization 4 (ISO 4) abbreviation of Cardiovascular and Hematological Disorders - Drug Targets is Cardiovasc. Hematol. Disord. - Drug Targets. ISO 4 is an international standard which defines a uniform and consistent system for the abbreviation of serial publication titles, which are published regularly. The primary use of ISO 4 is to abbreviate or shorten the names of scientific journals using the technique of List of Title Word Abbreviations (LTWA).

As ISO 4 is an international standard, the abbreviation ('Cardiovasc. Hematol. Disord. - Drug Targets') can be used for citing, indexing, abstraction, and referencing purposes.


How to publish in Cardiovascular and Hematological Disorders - Drug Targets


If your area of research or discipline is related to Cardiology and Cardiovascular Medicine, Hematology, Medicine (miscellaneous), Pharmacology, Molecular Medicine, etc., please check the journal's official website to understand the complete publication process.


Acceptance Rate


There are several factors that influence the acceptance rate of any academic journal. Here are some critical parameters that are considered while calculating the acceptance rate:

  • Interest/demand of researchers/scientists for publishing in a specific journal/conference.
  • The complexity of the peer review process and timeline.
  • Time taken from draft submission to final publication.
  • Number of submissions received and acceptance slots
  • And Many More.

The simplest way to find out the acceptance rate or rejection rate of a Journal/Conference is to check with the journal's/conference's editorial team through emails or through the official website.



Frequently Asked Questions (FAQ)


What is the impact score of Cardiovascular and Hematological Disorders - Drug Targets?

The latest impact score of Cardiovascular and Hematological Disorders - Drug Targets is 1.08. It is computed in the year 2023.


What is the h-index of Cardiovascular and Hematological Disorders - Drug Targets?

The latest h-index of Cardiovascular and Hematological Disorders - Drug Targets is 44. It is evaluated in the year 2023.


What is the SCImago Journal Rank (SJR) of Cardiovascular and Hematological Disorders - Drug Targets?

The latest SCImago Journal Rank (SJR) of Cardiovascular and Hematological Disorders - Drug Targets is 0.270. It is calculated in the year 2023.


What is the ranking of Cardiovascular and Hematological Disorders - Drug Targets?

The latest ranking of Cardiovascular and Hematological Disorders - Drug Targets is 16147. This ranking is among 27955 Journals, Conferences, and Book Series. It is computed in the year 2023.


Who is the publisher of Cardiovascular and Hematological Disorders - Drug Targets?

Cardiovascular and Hematological Disorders - Drug Targets is published by Bentham Science Publishers B.V.. The publication country of this journal is United Arab Emirates.


What is the abbreviation of Cardiovascular and Hematological Disorders - Drug Targets?

This standard abbreviation of Cardiovascular and Hematological Disorders - Drug Targets is Cardiovasc. Hematol. Disord. - Drug Targets.


Is "Cardiovascular and Hematological Disorders - Drug Targets" a Journal, Conference or Book Series?

Cardiovascular and Hematological Disorders - Drug Targets is a journal published by Bentham Science Publishers B.V..


What is the scope of Cardiovascular and Hematological Disorders - Drug Targets?

The scope of Cardiovascular and Hematological Disorders - Drug Targets is as follows:

  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Medicine (miscellaneous)
  • Pharmacology
  • Molecular Medicine

For detailed scope of Cardiovascular and Hematological Disorders - Drug Targets, check the official website of this journal.


What is the ISSN of Cardiovascular and Hematological Disorders - Drug Targets?

The International Standard Serial Number (ISSN) of Cardiovascular and Hematological Disorders - Drug Targets is/are as follows: 1871529X.


What is the best quartile for Cardiovascular and Hematological Disorders - Drug Targets?

The best quartile for Cardiovascular and Hematological Disorders - Drug Targets is Q3.


What is the coverage history of Cardiovascular and Hematological Disorders - Drug Targets?

The coverage history of Cardiovascular and Hematological Disorders - Drug Targets is as follows 2006-2022.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/
  • Issn.org, https://www.issn.org/
  • Scopus, https://www.scopus.com/

Note: The impact score shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.


Impact Score, SJR, h-Index, and Other Important metrics of These Journals, Conferences, and Book Series


Journal/Conference/Book Title Type Publisher Ranking SJR h-index Impact Score
Dermatologia Kliniczna Journal Cornetis 25442 7 0.00
Indian Journal of Plastic Surgery Journal Thieme Medical Publishers Inc. 16018 37 0.65
Entrepreneurship Theory and Practice Journal Wiley-Blackwell 338 185 12.75
World Englishes Journal Wiley-Blackwell 4960 60 1.97
Abacus Journal Wiley-Blackwell Publishing Ltd 8398 49 2.52
Studies in Continuing Education Journal Routledge 6011 38 2.81
Asian Textile Journal Trade Journal G P S Kwatra 27455 10 0.01
Physics and Chemistry of the Earth Journal Pergamon Press Ltd. 12927 33 0.00
Psycho-Oncologie Journal Springer Paris 24009 11 0.13
Transactions on Embedded Computing Systems Journal Association for Computing Machinery (ACM) 6019 61 2.25

Check complete list




Cardiovascular and Hematological Disorders - Drug Targets Impact Score (IS) Trend

Table: Impact Score

Year Impact Score (IS)
2023/2024 Updated Soon
2022 1.08
2021 1.09
2020 1.57
2019 1.41
2018 1.00
2017 1.13
2016 1.33
2015 1.81
2014 1.78



Top Journals/Conferences in Cardiology and Cardiovascular Medicine

Journal of the American College of Cardiology
Elsevier USA | United States

Circulation
Lippincott Williams and Wilkins Ltd. | United States

JAMA Cardiology
American Medical Association | United States

Nature Reviews Cardiology
Nature Publishing Group | United Kingdom

European Journal of Heart Failure
Wiley-Blackwell | United States

JACC: Heart Failure
Elsevier BV | Netherlands

Circulation Research
Lippincott Williams and Wilkins Ltd. | United States

JACC: Cardiovascular Imaging
Elsevier Inc. | United States

European Heart Journal
Oxford University Press | United Kingdom

Circulation: Heart Failure
Lippincott Williams and Wilkins Ltd. | United States

Circulation: Arrhythmia and Electrophysiology
Lippincott Williams and Wilkins Ltd. | United States

Circulation. Genomic and precision medicine
Lippincott Williams and Wilkins Ltd. | United States

JACC: Cardiovascular Interventions
Elsevier Inc. | United States

Arteriosclerosis, Thrombosis, and Vascular Biology
Lippincott Williams and Wilkins Ltd. | United States

Stroke
American Heart Association | United States

See All

Top Journals/Conferences in Hematology

Ca-A Cancer Journal for Clinicians
Wiley-Blackwell | United States

Annals of Oncology
Elsevier Ltd. | United Kingdom

Journal of Hematology and Oncology
BioMed Central Ltd. | United Kingdom

Blood
Elsevier BV | United States

Lancet Haematology,The
Lancet Publishing Group | United Kingdom

Blood Cancer Journal
Nature Publishing Group | United States

Leukemia
Nature Publishing Group | United Kingdom

Journal of Thrombosis and Haemostasis
Wiley-Blackwell Publishing Ltd | United Kingdom

Blood advances
Elsevier BV | United States

American Journal of Hematology
Wiley-Liss Inc. | United States

Blood Reviews
Churchill Livingstone | United States

Journal of the National Cancer Center
Chinese National Cancer Center | China

Haematologica
Ferrata Storti Foundation | Italy

Experimental Hematology and Oncology
BioMed Central Ltd. | United Kingdom

Radiotherapy and Oncology
Elsevier Ireland Ltd | Ireland

See All

Top Journals/Conferences in Medicine (miscellaneous)

New England Journal of Medicine
Massachussetts Medical Society | United States

Nature Medicine
Nature Publishing Group | United Kingdom

MMWR Recommendations and Reports
Centers for Disease Control and Prevention (CDC) | United States

Nature Reviews Drug Discovery
Nature Publishing Group | United Kingdom

Nature Reviews Immunology
Nature Publishing Group | United Kingdom

Morbidity and Mortality Weekly Report
Department of Health and Human Services | United States

Lancet, The
Elsevier Ltd. | United Kingdom

Physiological Reviews
American Physiological Society | United States

MMWR supplements
Epidemiology Program Office | United States

Annals of Oncology
Elsevier Ltd. | United Kingdom

Nature Reviews Disease Primers
Nature Publishing Group | United Kingdom

Current Protocols in Bioinformatics
John Wiley & Sons Inc. | United States

Journal of Clinical Oncology
Lippincott Williams and Wilkins Ltd. | United States

Annual Review of Public Health
Annual Reviews Inc. | United States

Nature Reviews Methods Primers
Springer Nature | United States

See All

Top Journals/Conferences in Pharmacology

Nature Reviews Drug Discovery
Nature Publishing Group | United Kingdom

Pharmacological Reviews
American Society for Pharmacology and Experimental Therapeutics | United States

Drug Resistance Updates
Churchill Livingstone | United States

Annual Review of Pharmacology and Toxicology
Annual Reviews Inc. | United States

Molecular Therapy
Cell Press | United States

Journal for ImmunoTherapy of Cancer
BMJ Publishing Group | United Kingdom

npj Vaccines
Nature Publishing Group | United Kingdom

Pharmacology and Therapeutics
Elsevier Inc. | United States

Trends in Pharmacological Sciences
Elsevier Ltd. | United Kingdom

Alimentary Pharmacology and Therapeutics
Wiley-Blackwell Publishing Ltd | United Kingdom

American Journal of Transplantation
Wiley-Blackwell Publishing Ltd | United Kingdom

Medicinal Research Reviews
John Wiley & Sons Inc. | United States

Cell Chemical Biology
Elsevier Inc. | United States

Journal of Biomedical Science
BioMed Central Ltd. | United Kingdom

Acta Pharmaceutica Sinica B
Elsevier BV | Netherlands

See All

Top Journals/Conferences in Molecular Medicine

Nature Biotechnology
Nature Publishing Group | United Kingdom

Cell Stem Cell
Cell Press | United States

Molecular Cancer
BioMed Central Ltd. | United Kingdom

Pharmacological Reviews
American Society for Pharmacology and Experimental Therapeutics | United States

Genome Medicine
BioMed Central Ltd. | United Kingdom

EMBO Molecular Medicine
Wiley-Blackwell | United Kingdom

Molecular Therapy
Cell Press | United States

Journal for ImmunoTherapy of Cancer
BMJ Publishing Group | United Kingdom

Experimental and Molecular Medicine
Korean Society of Med. Biochemistry and Mol. Biology | South Korea

Molecular Aspects of Medicine
Elsevier Ltd. | United Kingdom

Trends in Molecular Medicine
Elsevier Ltd. | United Kingdom

Medicinal Research Reviews
John Wiley & Sons Inc. | United States

Cell Chemical Biology
Elsevier Inc. | United States

Biomarker Research
BioMed Central Ltd. | United Kingdom

Cellular and Molecular Life Sciences
Birkhauser Verlag Basel | Switzerland

See All